Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qinghua Bihui Granules for Mild COVID-19
ChiCTR2200060294Phase 4Recruiting
- Sponsor
- Jiujiang Hospital of Traditional Chinese Medicine
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Qinghua Bihui in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Jiujiang Hospital of Traditional Chinese Medicine. Primary endpoints: Nucleic acid turning negative time and Nucleic acid conversion rate. Started Apr 2022; status: recruiting.
02
Drugs
Qinghua Bihui
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200060294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060294.